Another blood pressure drug recalled due to cancer risk

Pearl Mccarthy
March 6, 2019

Camber made the recall in cooperation with the U.S. Food and Drug Administration. If patients take an ARB drug product, they should check the list periodically, as information may change.

"That said, any presence of such impurities in drug products is not acceptable", FDA Commissioner Scott Gottlieb said in the statement.

Since last summer, drug companies have recalled hundreds of lots of blood pressure and heart medication drugs after tests showed small levels of potentially cancer-causing impurities.

Camber Pharmaceuticals, Inc. recalled 87 numerous the blood stress remedy losartan on Thursday after discovering hint quantities of a possible carcinogen. The active ingredient in each came from India-based Hetero Labs Limited.

Camber's recall is the second in a week of Losartan tablets.

More than 1,500 live turtles found duct-taped and stuffed in suitcases
In 2018, airport officials confiscated over 250 geckos, plus another 250 corals and other reptiles in bags and parcels. Authorities had already intercepted 63 iguanas, chameleon and bearded dragons earlier this year.

Another blood pressure medication has been recalled over concerns it could contain trace amounts of carcinogens.

The previous recalls of Losarta, Valsartan or Irbesartan involved too much N-Nitrosodiethylamine (NDEA) or N-nitrosodimethylamine (NDMA).

Recent FDA analyses of NDMA and NDEA in the recalled drugs have found that "overall, the risk to individual patients is very low", but the agency added that those findings don't diminish the significance of this issue and that it continues to evaluate the risks posed to patients. The recalled medication is half of a giant class of medicine referred to as angiotensin II receptor blockers, or ARBs, which work by enjoyable the blood vessels. FDA scientists have developed novel and sophisticated testing methods specifically created to detect and measure N-Nitrosodimethylamine (NDMA) and N-Nitrosodiethylamine (NDEA) impurities in ARB medicines. Zhejiang Huahai has said it has been in close contact with the FDA since the recall began.

The FDA said Torrent Pharmaceuticals Ltd is expanding its voluntary recall to include 114 additional lots of losartan-containing medication due to unacceptable amounts of NMBA in the losartan manufactured by Hetero Labs. It's the first ARB recall involving the presence of NMBA, which is the third type of nitrosamine impurity detected in the medications, the FDA said.

Other reports by

Discuss This Article